- Report
- March 2024
- 184 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- November 2023
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- June 2023
- 338 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- October 2023
- 145 Pages
Global
From €3040EUR$3,150USD£2,608GBP
- Report
- December 2023
- 140 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- August 2020
- 114 Pages
Global
From €4102EUR$4,250USD£3,519GBP
- Report
- April 2023
- 180 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- October 2018
- 104 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- December 2018
- 48 Pages
Global
From €3373EUR$3,495USD£2,894GBP
- Report
- November 2020
- 199 Pages
Global
€4343EUR$4,500USD£3,726GBP
- Report
- January 2021
- 149 Pages
China, Global
From €3000EUR$3,330USD£2,663GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more